Fundraising Fox5AM Ventures — 2018 Investments
6 investments dated 2018 · listed companies and verified rows first · show all
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.
BiotechHealthtechRadnor, US
Steven Nichtberger(Founder)inDan Geffken(Executive Officer)inAnup Marda(Chief Financial Officer)inMark Simon(Director)
Board seatBrian Daniels· per SEC Form D
Co-investorsBain Capital Life SciencesDeerfield Management Company
Stoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.
BiotechBedford, US
Adrian Krainer(Executive Officer, Director, Promoter)Isabel Aznarez(Executive Officer, Director, Promoter)inHuw Nash(Executive Officer)inIan F. Smith(Chief Executive Officer and Director)Jason Hoitt(Chief Patient Officer)inThomas E. Leggett(Chief Financial Officer)
Board seatArthur Tzianabos· per SEC Form D · $90M raise · filed Nov 2018
Co-investorsScion Life SciencesRTW Investments L.P.
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Board seatKush M ParmarArthur Tzianabos· per SEC Form D
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Pivotal Life SciencesRA CapitalSofinnova VenturesCowen Healthcare Investments+2 more
Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.
BiotechSan Diego, US
Alain Baron(Founder)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Founder)
BoardAndrew Schwab(Director)in
Co-investorsAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column GroupAbingworth+2 more
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)inChris Guiffre(Executive Team)inAlan P. Watt(Executive Team)inJyothis George(Chief Medical Officer)inNick Clarke(Executive Team)in
Co-investorsEpidarex CapitalF-Prime CapitalSanofi VenturesSofinnova Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.